References
Baccarani M, Saglio J, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al., European Leukemia Net. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143–5150.
Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and –beta during human testicular development and disease. J Clin Endocrinol Metab 2002; 87: 2310–2319.
Cheng J, Watkins SC, Walker WH . Testosterone activates mitogen-activated protein kinase via Src kinase and the epidermal growth factor receptor in Sertoli cells. Endocrinology 2007; 148: 2066–2074.
Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L et al. Gynaecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003; 361: 1954–1956.
Kim H, Chang HM, Ryu MH, Kim TW, Sohn HJ, Kim SE et al. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. J Korean Med Sci 2005; 20: 512–515.
Walz C, Sattler M . Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Critic Rew Oncol Hematol 2006; 57: 145–164.
Sprenkle PC, Fish H . Pathologic effects of testosterone deprivation. Curr Opin Urol 2007; 17: 424–430.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caocci, G., Atzeni, S., Orrù, N. et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia 22, 2127–2128 (2008). https://doi.org/10.1038/leu.2008.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.106
- Springer Nature Limited
This article is cited by
-
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
Journal of Endocrinological Investigation (2022)
-
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib
Annals of Hematology (2021)
-
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
Blood Cancer Journal (2020)
-
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors
Annals of Hematology (2020)
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
Leukemia (2016)